Figure 4From: Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPDDifferences and 95% confidence intervals between roflumilast and placebo for changes in St George's Respiratory Questionnaire (SGRQ) total score by patient subgroup. Error bars represent 95% CIs.Back to article page